Analgesics Market by Type (Non-opioids, Opioids) and Route of Administration (Oral, Intravenous, Rectal, Transdermal, Topical) - Global Opportunity Analysis and Industry Forecast, 2015 - 2022
Analgesics, also known as painkillers, are used to treat and reduce pain in the body. Typically, they are used when the pain is severe and becomes unbearable for the patient. Non-opioids, opioids, and compound analgesics (a combination of both opioids and non-opioids) are the major analgesic products used globally. The emergence of analgesics is mainly attributed to the increase in acute and chronic diseases, as well as the rising incidence of cancer worldwide.
Opioid drugs are the strongest types of analgesics, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only.
The world analgesics market is expected to achieve moderate growth in the near future, majorly because of factors such as increase in cardiovascular disease, cancer, and arthritis and growing geriatric population. Recurring pain and aches experienced by the ageing population is another factor the helps the market growth. In addition, increasing investments in R&D by the public and private sector, with key emphasis on the classes of compounds for formulating new therapeutics, are further expected to drive the market. However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are likely to restrain the growth of the market.
The report segments the analgesics market on the basis of type, route of administration, and geography. On the basis of type, the market is segmented into non-opioids and opioids. According to the route of administration, it is segmented into oral, intravenous, rectal, transdermal, and topical. Based on the geography, it is categorized into North America, Europe, Asia-Pacific, andLAMEA.
Companies adopt acquisition as their key development strategy in the analgesic market. A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS:
Opioid drugs are the strongest types of analgesics, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only.
The world analgesics market is expected to achieve moderate growth in the near future, majorly because of factors such as increase in cardiovascular disease, cancer, and arthritis and growing geriatric population. Recurring pain and aches experienced by the ageing population is another factor the helps the market growth. In addition, increasing investments in R&D by the public and private sector, with key emphasis on the classes of compounds for formulating new therapeutics, are further expected to drive the market. However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are likely to restrain the growth of the market.
The report segments the analgesics market on the basis of type, route of administration, and geography. On the basis of type, the market is segmented into non-opioids and opioids. According to the route of administration, it is segmented into oral, intravenous, rectal, transdermal, and topical. Based on the geography, it is categorized into North America, Europe, Asia-Pacific, andLAMEA.
Companies adopt acquisition as their key development strategy in the analgesic market. A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS:
- This report includes a detailed quantitative analysis of the current market trends and estimations from 2015 to 2022, which assists in identifying the prevailing market opportunities.
- Geographically, the analgesics market is analyzed based on key regions such as North America, Europe, Asia-Pacific, andLAMEA.
- This study evaluates the competitive landscape of the analgesics market to aid the reader in understanding the competitive environment across the geographic locations.
- Furthermore, key market players within this market have been profiled in this report and their strategies are analyzed thoroughly. This helps in understanding the competitive outlook on the supply side of the market.
- Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
- Porters Five Forces analysis extensively covers the perspective of buyers and suppliers, along with the competitive rivalry among companies.
- SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.
- By Type
- Non-opioids
- Opioids
- By Route of Administration
- Oral
- Intravenous
- Rectal
- Transdermal
- Topical
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- Spain
- Sweden
- France
- Russia
- Denmark
- Rest of EU
- Asia-Pacific
- Japan
- China
- India
- Australia
- Indonesia
- Rest of APAC
- LAMEA
- Brazil
- Venezuela
- Chile
- Saudi Arabia
- UAE
- Morocco
- Kenya
- Nigeria
- Rest ofLAMEA
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2027
2.2.1 Base case scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Low bargaining power of supplier
3.3.2 Moderate bargaining power of buyers
3.3.3 Low threat of new entrants
3.3.4 Moderate threat of substitute
3.3.5 Moderate competitive rivalry
3.4 Government regulations
3.5 Research & Analysis
3.5.1 Clinical trials of research studies conducted for analgesics market
3.6 Market dynamics
3.6.1 Drivers
3.6.2 Restraints
3.6.3 Opportunities
CHAPTER 4 WORLD ANALGESICS MARKET, BY TYPE, 2015-2022
4.1 Overview
4.1.1 Market size and forecast
4.2 Non-opioids
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Opioids
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
CHAPTER 5 WORLD ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022
5.1 Oral route
5.1.1 Market size and forecast
5.2 Intravenous route
5.2.1 Market size and forecast
5.3 Rectal route
5.3.1 Market size and forecast
5.4 Transdermal route
5.4.1 Market size and forecast
5.5 Topical route
5.5.1 Market size and forecast
CHAPTER 6 WORLD ANALGESICS MARKET BY GEOGRAPHY, 2015-2022
6.1 North America
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.1.4 United states
6.1.4.1 Market size and forecast
6.1.5 Canada
6.1.5.1 Market size and forecast
6.1.6 Mexico
6.1.6.1 Market size and forecast
6.2 Europe
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 United Kingdom
6.2.4.1 Market size and forecast
6.2.5 Germany
6.2.5.1 Market size and forecast
6.2.6 Spain
6.2.6.1 Market size and forecast
6.2.7 Sweden
6.2.7.1 Market size and forecast
6.2.8 France
6.2.8.1 Market size and forecast
6.2.9 Russia
6.2.9.1 Market size and forecast
6.2.10 Denmark
6.2.10.1 Market size and forecast
6.2.11 Rest of Europe
6.2.11.1 Market size and forecast
6.3 Asia Pacific
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.3.4 Japan
6.3.4.1 Market size and forecast
6.3.5 China
6.3.5.1 Market size and forecast
6.3.6 India
6.3.6.1 Market size and forecast
6.3.7 Australia
6.3.7.1 Market size and forecast
6.3.8 Indonesia
6.3.8.1 Market size and forecast
6.3.9 Rest of Asia-Pacific
6.3.9.1 Market size and forecast
6.4 LAMEA
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Brazil
6.4.4.1 Market size and forecast
6.4.5 Venezuela
6.4.5.1 Market size and forecast
6.4.6 Chile
6.4.6.1 Market size and forecast
6.4.7 Saudi Arabia
6.4.7.1 Market size and forecast
6.4.8 United Arab Emirates (UAE)
6.4.8.1 Market size and forecast
6.4.9 Morocco
6.4.9.1 Market size and forecast
6.4.10 Kenya
6.4.10.1 Market size and forecast
6.4.11 Nigeria
6.4.11.1 Market size and forecast
6.4.12 Rest ofLAMEA
6.4.12.1 Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Bayer AG
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Business performance
7.1.5 Key Strategic moves and developments
7.1.6 SWOT analysis
7.2 Novartis AG
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Business performance
7.2.5 Key strategic moves and development
7.2.6 SWOT analysis
7.3 GlaxoSmithKline PLC
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Business performance
7.3.5 Key strategies move and development
7.3.6 SWOT Analysis
7.4 Pfizer Inc.
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Business performance
7.4.5 Strategic moves and developments
7.4.6 SWOT analysis
7.5 Johnson & Johnson
7.5.1 Company Overview
7.5.2 Company Snapshot
7.5.3 Operating business segments
7.5.4 Business performance
7.5.5 Key strategic moves and developments
7.5.6 SWOT analysis
7.6 Reckitt Benckiser (RB)
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Business performance
7.6.5 SWOT analysis
7.7 Endo Pharmaceuticals
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Business performance
7.7.5 Key strategic moves and developments
7.7.6 SWOT analysis
7.8 Bristol-Myers Squibb
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Key strategic moves and developments
7.8.5 SWOT analysis
7.9 Eli Lilly and Company
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Business performance
7.9.5 Key strategic moves and developments
7.9.6 SWOT analysis
7.10 Sanofi
7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Operating business segments
7.10.4 Business performance
7.10.5 Strategic moves and developments
7.10.6 SWOT analysis
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2027
2.2.1 Base case scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Low bargaining power of supplier
3.3.2 Moderate bargaining power of buyers
3.3.3 Low threat of new entrants
3.3.4 Moderate threat of substitute
3.3.5 Moderate competitive rivalry
3.4 Government regulations
3.5 Research & Analysis
3.5.1 Clinical trials of research studies conducted for analgesics market
3.6 Market dynamics
3.6.1 Drivers
3.6.2 Restraints
3.6.3 Opportunities
CHAPTER 4 WORLD ANALGESICS MARKET, BY TYPE, 2015-2022
4.1 Overview
4.1.1 Market size and forecast
4.2 Non-opioids
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Opioids
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
CHAPTER 5 WORLD ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022
5.1 Oral route
5.1.1 Market size and forecast
5.2 Intravenous route
5.2.1 Market size and forecast
5.3 Rectal route
5.3.1 Market size and forecast
5.4 Transdermal route
5.4.1 Market size and forecast
5.5 Topical route
5.5.1 Market size and forecast
CHAPTER 6 WORLD ANALGESICS MARKET BY GEOGRAPHY, 2015-2022
6.1 North America
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.1.4 United states
6.1.4.1 Market size and forecast
6.1.5 Canada
6.1.5.1 Market size and forecast
6.1.6 Mexico
6.1.6.1 Market size and forecast
6.2 Europe
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 United Kingdom
6.2.4.1 Market size and forecast
6.2.5 Germany
6.2.5.1 Market size and forecast
6.2.6 Spain
6.2.6.1 Market size and forecast
6.2.7 Sweden
6.2.7.1 Market size and forecast
6.2.8 France
6.2.8.1 Market size and forecast
6.2.9 Russia
6.2.9.1 Market size and forecast
6.2.10 Denmark
6.2.10.1 Market size and forecast
6.2.11 Rest of Europe
6.2.11.1 Market size and forecast
6.3 Asia Pacific
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.3.4 Japan
6.3.4.1 Market size and forecast
6.3.5 China
6.3.5.1 Market size and forecast
6.3.6 India
6.3.6.1 Market size and forecast
6.3.7 Australia
6.3.7.1 Market size and forecast
6.3.8 Indonesia
6.3.8.1 Market size and forecast
6.3.9 Rest of Asia-Pacific
6.3.9.1 Market size and forecast
6.4 LAMEA
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Brazil
6.4.4.1 Market size and forecast
6.4.5 Venezuela
6.4.5.1 Market size and forecast
6.4.6 Chile
6.4.6.1 Market size and forecast
6.4.7 Saudi Arabia
6.4.7.1 Market size and forecast
6.4.8 United Arab Emirates (UAE)
6.4.8.1 Market size and forecast
6.4.9 Morocco
6.4.9.1 Market size and forecast
6.4.10 Kenya
6.4.10.1 Market size and forecast
6.4.11 Nigeria
6.4.11.1 Market size and forecast
6.4.12 Rest ofLAMEA
6.4.12.1 Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Bayer AG
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Business performance
7.1.5 Key Strategic moves and developments
7.1.6 SWOT analysis
7.2 Novartis AG
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Business performance
7.2.5 Key strategic moves and development
7.2.6 SWOT analysis
7.3 GlaxoSmithKline PLC
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Business performance
7.3.5 Key strategies move and development
7.3.6 SWOT Analysis
7.4 Pfizer Inc.
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Business performance
7.4.5 Strategic moves and developments
7.4.6 SWOT analysis
7.5 Johnson & Johnson
7.5.1 Company Overview
7.5.2 Company Snapshot
7.5.3 Operating business segments
7.5.4 Business performance
7.5.5 Key strategic moves and developments
7.5.6 SWOT analysis
7.6 Reckitt Benckiser (RB)
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Business performance
7.6.5 SWOT analysis
7.7 Endo Pharmaceuticals
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Business performance
7.7.5 Key strategic moves and developments
7.7.6 SWOT analysis
7.8 Bristol-Myers Squibb
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Key strategic moves and developments
7.8.5 SWOT analysis
7.9 Eli Lilly and Company
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Business performance
7.9.5 Key strategic moves and developments
7.9.6 SWOT analysis
7.10 Sanofi
7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Operating business segments
7.10.4 Business performance
7.10.5 Strategic moves and developments
7.10.6 SWOT analysis
LIST OF TABLES
TABLE 1 WORLD ANALGESICS MARKETBASE CASE SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
TABLE 2 WORLD ANALGESICS MARKET RAPID GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
TABLE 3 WORLD ANALGESICS MARKET DIMINISHING GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
TABLE 4 PORTERS FIVE FORCES ANALYSIS
TABLE 5 CLINICAL TRIALS - ANALGESICS
TABLE 6 GLOBAL INCIDENCES OF DISEASES
TABLE 7 WORLD ANALGESICS MARKET, BY TYPE, 2015-2022 ($MILLION)
TABLE 8 WORLD NON-OPIOIDS ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 9 WORLD OPIOID ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 10 WORLD ANALGESICS MARKET BY ROUTE OF ADMINISTRATION, 2015-2022 ($MILLION)
TABLE 11 WORLD ANALGESICS ORAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 12 WORLD ANALGESICS INTRAVENOUS ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 13 WORLD ANALGESICS RECTAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 14 WORLD ANALGESICS TRANSDERMAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 15 WORLD ANALGESICS TOPICAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 16 WORLD ANALGESICS MODE OF APPLICATION BY TYPE, 2015-2022 ($MILLION)
TABLE 17 WORLD ANALGESICS MODE OF APPLICATION BY TYPE, 2015-2022 ($MILLION)
TABLE 18 WORLD ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 19 NORTH AMERICA ANALGESICS MARKET, BY TYPE, 2015-2022 ($MILLION)
TABLE 20 NORTH AMERICA ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 21 EUROPE ANALGESICS MARKET, BY TYPES, 2015-2022 ($MILLION)
TABLE 22 EUROPE ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 23 ASIA PACIFIC ANALGESIC MARKET, BY TYPES, 2015-2022 ($MILLION)
TABLE 24 ASIA PACIFIC ANALGESIC MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 25 LAMEA ANALGESICS MARKET, BY TYPES, 2015-2022 ($MILLION)
TABLE 26 LAMEA ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 27 COMPANY SNAPSHOT OF BAYER AG
TABLE 28 BAYER AG OPERATING SEGMENTS
TABLE 29 COMPANY SNAPSHOT OF NOVARTIS AG
TABLE 30 NOVARTIS AG OPERATINGSEGEMENTS
TABLE 31 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 32 GLAXOSMITHKLINE PLC OPERATINGSEGEMENTS
TABLE 33 COMPANY SNAPSHOT OF PFIZER INC.
TABLE 34 PFIZER INC. OPERATING SEGMENTS
TABLE 35 COMPANY SNAPSHOT OF JOHNSON &JOHSNON
TABLE 36 JOHNSON &JOHSNON OPERATING SEGMENTS
TABLE 37 COMPANY SNAPSHOT OF RB
TABLE 38 RECKITT BENCKISER OPERATING SEGMENTS
TABLE 39 COMPANY SNAPSHOT OF ENDO PHARMACEUTICALS
TABLE 40 ENDO PHARMACEUTICALS OPERATING SEGMENTS
TABLE 41 COMPANY SNAPSHOT OF BRISTOL-MYERS SQUIBB
TABLE 42 COMPANY SNAPSHOT OF ELI LILY AND COMPANY
TABLE 43 ELI LILY OPERATING SEGMENTS
TABLE 44 COMPANY SNAPSHOT OF SANOFI
TABLE 45 SANOFI OPERATING SEGMENTS
TABLE 1 WORLD ANALGESICS MARKETBASE CASE SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
TABLE 2 WORLD ANALGESICS MARKET RAPID GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
TABLE 3 WORLD ANALGESICS MARKET DIMINISHING GROWTH SCENARIO MARKET, BY GEOGRAPHY, 2022 2027 ($MILLION)
TABLE 4 PORTERS FIVE FORCES ANALYSIS
TABLE 5 CLINICAL TRIALS - ANALGESICS
TABLE 6 GLOBAL INCIDENCES OF DISEASES
TABLE 7 WORLD ANALGESICS MARKET, BY TYPE, 2015-2022 ($MILLION)
TABLE 8 WORLD NON-OPIOIDS ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 9 WORLD OPIOID ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 10 WORLD ANALGESICS MARKET BY ROUTE OF ADMINISTRATION, 2015-2022 ($MILLION)
TABLE 11 WORLD ANALGESICS ORAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 12 WORLD ANALGESICS INTRAVENOUS ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 13 WORLD ANALGESICS RECTAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 14 WORLD ANALGESICS TRANSDERMAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 15 WORLD ANALGESICS TOPICAL ROUTE MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 16 WORLD ANALGESICS MODE OF APPLICATION BY TYPE, 2015-2022 ($MILLION)
TABLE 17 WORLD ANALGESICS MODE OF APPLICATION BY TYPE, 2015-2022 ($MILLION)
TABLE 18 WORLD ANALGESICS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 19 NORTH AMERICA ANALGESICS MARKET, BY TYPE, 2015-2022 ($MILLION)
TABLE 20 NORTH AMERICA ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 21 EUROPE ANALGESICS MARKET, BY TYPES, 2015-2022 ($MILLION)
TABLE 22 EUROPE ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 23 ASIA PACIFIC ANALGESIC MARKET, BY TYPES, 2015-2022 ($MILLION)
TABLE 24 ASIA PACIFIC ANALGESIC MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 25 LAMEA ANALGESICS MARKET, BY TYPES, 2015-2022 ($MILLION)
TABLE 26 LAMEA ANALGESICS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 27 COMPANY SNAPSHOT OF BAYER AG
TABLE 28 BAYER AG OPERATING SEGMENTS
TABLE 29 COMPANY SNAPSHOT OF NOVARTIS AG
TABLE 30 NOVARTIS AG OPERATINGSEGEMENTS
TABLE 31 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 32 GLAXOSMITHKLINE PLC OPERATINGSEGEMENTS
TABLE 33 COMPANY SNAPSHOT OF PFIZER INC.
TABLE 34 PFIZER INC. OPERATING SEGMENTS
TABLE 35 COMPANY SNAPSHOT OF JOHNSON &JOHSNON
TABLE 36 JOHNSON &JOHSNON OPERATING SEGMENTS
TABLE 37 COMPANY SNAPSHOT OF RB
TABLE 38 RECKITT BENCKISER OPERATING SEGMENTS
TABLE 39 COMPANY SNAPSHOT OF ENDO PHARMACEUTICALS
TABLE 40 ENDO PHARMACEUTICALS OPERATING SEGMENTS
TABLE 41 COMPANY SNAPSHOT OF BRISTOL-MYERS SQUIBB
TABLE 42 COMPANY SNAPSHOT OF ELI LILY AND COMPANY
TABLE 43 ELI LILY OPERATING SEGMENTS
TABLE 44 COMPANY SNAPSHOT OF SANOFI
TABLE 45 SANOFI OPERATING SEGMENTS
LIST OF FIGURES
FIG. 1 TOP IMPACTING FACTORS, BASE CASE SCENARIO (2022-2027)
FIG. 2 TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2022-2027)
FIG. 3 TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2022-2027)
FIG. 4 TOP INVESTMENT POCKETS OF ANALGESICS MARKET BY ROUTE OF ADMINISTRATION, 2015-2022
FIG. 5 TOP WINNING STRATEGIES
FIG. 6 TOP FACTORS IMPACTING WORLD ANALGESICS MARKET, 2015-2022
FIG. 7 DRUG POISONING DEATHS INVOLVING OPIOID ANALGESICS
FIG. 8 LEADING INTERNAL ANALGESIC TABLET BRANDS, 2015, BASED ON SALES ($MILLION)
FIG. 9 UNITED STATES ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 10 CANADA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 11 MEXICO ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 12 UNITED KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 13 GERMANY KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 14 SPAIN KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 15 SWEDEN ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 16 FRANCE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 17 RUSSIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 18 DENMARK ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 19 REST OF EUROPE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 20 JAPAN ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 21 CHINA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 22 INDIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 23 AUSTRALIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 24 INDONESIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 25 REST OF ASIA-PACIFIC ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 26 BRAZIL ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 27 VENEZUELA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 28 CHILE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 29 SAUDI ARABIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 30 UAE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 31 MOROCCO ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 32 KENYA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 33 NIGERIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 34 LAMEA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 35 REVENUE GENERATED BY BAYER AG (2012-2014)
FIG. 36 BAYER AG, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 37 BAYER AG, % REVENUE, BY GEOGRAPHY (2014)
FIG. 38 SWOT ANALYSIS OF BAYER AG
FIG. 39 REVENUE GENERATED BY NOVARTIS AG (2012-2014)
FIG. 40 NOVARTIS AG, % REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 41 NOVARTIS AG. % REVENUE BY GEOGRAPHY (2014)
FIG. 42 SWOT ANALYSIS OF NOVARTIS AG
FIG. 43 REVENUE GENERATED BY GLAXOSMITHKLINE PLC (2012-2014)
FIG. 44 GLAXOSMITHKLINE PLC, % REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 45 GLAXOSMITHKLINE PLC, % REVENUE BY GEOGRAPHY (2014)
FIG. 46 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 47 REVENUE GENERATED BY PFIZER INC. (2012-2014)
FIG. 48 PFIZER INC., %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 49 PFIZER INC., % REVENUE, BY GEOGRAPHY (2014)
FIG. 50 SWOT ANALYSIS OF PFIZER INC.
FIG. 51 REVENUE GENERATED BY JOHNSON & JOHNSON (2012-2014)
FIG. 52 JOHNSON & JOHNSON, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 53 JOHNSON & JOHNSON, % REVENUE, BY GEOGRAPHY (2014)
FIG. 54 SWOT ANALYSIS OF JOHNSON &JOHSNON
FIG. 55 REVENUE GENERATED BY RECKITT BENCKISER (2012-2014)
FIG. 56 RECKITT BENCKISER, % REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 57 RECKITT BENCKISER, % REVENUE, BY GEOGRAPHY (2014)
FIG. 58 SWOT ANALYSIS OF RECKITT BENCKISER
FIG. 59 REVENUE GENERATED BY ENDO PHARMACEUTICALS (2012-2014)
FIG. 60 ENDO PHARMACEUTICALS, % REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 61 SWOT ANALYSIS OF ENDO PHARMACEUTICALS
FIG. 62 REVENUE GENERATED BY BRISTOL-MYERS SQUIBB (2012-2014)
FIG. 63 BRISTOL-MYERS SQUIBB, % REVENUE, BY GEOGRAPHY (2014)
FIG. 64 SWOT ANALYSIS OF BRISTOL-MYERS SQUIBB
FIG. 65 REVENUE GENERATED BY ELI LILY (2012-2014)
FIG. 66 ELI LILY, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 67 ELI LILY, % REVENUE, BY GEOGRAPHY (2014)
FIG. 68 SWOT ANALYSIS OF ELI LILY
FIG. 69 REVENUE GENERATED BY SANOFI (2012-2014)
FIG. 70 SANOFI, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 71 SANOFI, %REVENUE, BY GEOGRAPHY (2014)
FIG. 72 SWOT ANALYSIS OF SANOFI
FIG. 1 TOP IMPACTING FACTORS, BASE CASE SCENARIO (2022-2027)
FIG. 2 TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2022-2027)
FIG. 3 TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2022-2027)
FIG. 4 TOP INVESTMENT POCKETS OF ANALGESICS MARKET BY ROUTE OF ADMINISTRATION, 2015-2022
FIG. 5 TOP WINNING STRATEGIES
FIG. 6 TOP FACTORS IMPACTING WORLD ANALGESICS MARKET, 2015-2022
FIG. 7 DRUG POISONING DEATHS INVOLVING OPIOID ANALGESICS
FIG. 8 LEADING INTERNAL ANALGESIC TABLET BRANDS, 2015, BASED ON SALES ($MILLION)
FIG. 9 UNITED STATES ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 10 CANADA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 11 MEXICO ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 12 UNITED KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 13 GERMANY KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 14 SPAIN KINGDOM ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 15 SWEDEN ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 16 FRANCE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 17 RUSSIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 18 DENMARK ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 19 REST OF EUROPE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 20 JAPAN ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 21 CHINA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 22 INDIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 23 AUSTRALIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 24 INDONESIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 25 REST OF ASIA-PACIFIC ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 26 BRAZIL ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 27 VENEZUELA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 28 CHILE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 29 SAUDI ARABIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 30 UAE ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 31 MOROCCO ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 32 KENYA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 33 NIGERIA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 34 LAMEA ANALGESICS MARKET REVENUE, 2015-2022, ($MILLION)
FIG. 35 REVENUE GENERATED BY BAYER AG (2012-2014)
FIG. 36 BAYER AG, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 37 BAYER AG, % REVENUE, BY GEOGRAPHY (2014)
FIG. 38 SWOT ANALYSIS OF BAYER AG
FIG. 39 REVENUE GENERATED BY NOVARTIS AG (2012-2014)
FIG. 40 NOVARTIS AG, % REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 41 NOVARTIS AG. % REVENUE BY GEOGRAPHY (2014)
FIG. 42 SWOT ANALYSIS OF NOVARTIS AG
FIG. 43 REVENUE GENERATED BY GLAXOSMITHKLINE PLC (2012-2014)
FIG. 44 GLAXOSMITHKLINE PLC, % REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 45 GLAXOSMITHKLINE PLC, % REVENUE BY GEOGRAPHY (2014)
FIG. 46 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 47 REVENUE GENERATED BY PFIZER INC. (2012-2014)
FIG. 48 PFIZER INC., %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 49 PFIZER INC., % REVENUE, BY GEOGRAPHY (2014)
FIG. 50 SWOT ANALYSIS OF PFIZER INC.
FIG. 51 REVENUE GENERATED BY JOHNSON & JOHNSON (2012-2014)
FIG. 52 JOHNSON & JOHNSON, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 53 JOHNSON & JOHNSON, % REVENUE, BY GEOGRAPHY (2014)
FIG. 54 SWOT ANALYSIS OF JOHNSON &JOHSNON
FIG. 55 REVENUE GENERATED BY RECKITT BENCKISER (2012-2014)
FIG. 56 RECKITT BENCKISER, % REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 57 RECKITT BENCKISER, % REVENUE, BY GEOGRAPHY (2014)
FIG. 58 SWOT ANALYSIS OF RECKITT BENCKISER
FIG. 59 REVENUE GENERATED BY ENDO PHARMACEUTICALS (2012-2014)
FIG. 60 ENDO PHARMACEUTICALS, % REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 61 SWOT ANALYSIS OF ENDO PHARMACEUTICALS
FIG. 62 REVENUE GENERATED BY BRISTOL-MYERS SQUIBB (2012-2014)
FIG. 63 BRISTOL-MYERS SQUIBB, % REVENUE, BY GEOGRAPHY (2014)
FIG. 64 SWOT ANALYSIS OF BRISTOL-MYERS SQUIBB
FIG. 65 REVENUE GENERATED BY ELI LILY (2012-2014)
FIG. 66 ELI LILY, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 67 ELI LILY, % REVENUE, BY GEOGRAPHY (2014)
FIG. 68 SWOT ANALYSIS OF ELI LILY
FIG. 69 REVENUE GENERATED BY SANOFI (2012-2014)
FIG. 70 SANOFI, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 71 SANOFI, %REVENUE, BY GEOGRAPHY (2014)
FIG. 72 SWOT ANALYSIS OF SANOFI
